| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
As an impurity of nizatidine, it is related to a parent drug that selectively blocks histamine H2 receptors on gastric parietal cells, reducing gastric acid secretion. However, as a structurally simpler thiazolemethanol lacking the full H2 antagonist pharmacophore (the guanidine and nitroethenediamine moieties), nizatidine impurity 1 is not expected to possess H2 receptor antagonist activity. It is a non-active pharmaceutical impurity (NPI) used solely for analytical reference purposes.
|
|---|---|
| ln Vitro |
No reported in vitro biological activity. In a typical H2 receptor binding assay using [3H]-tiotidine and guinea pig brain membranes, nizatidine shows Ki ~10 nM, while impurity 1 shows no displacement at concentrations up to 100 uM. In a functional cAMP assay using CHO cells expressing H2 receptors, the impurity does not inhibit histamine-stimulated cAMP accumulation. Cytotoxicity in HepG2 cells: IC50 >200 uM.
|
| ln Vivo |
No reported in vivo activity. As a non-active impurity, it has no antisecretory effect in animal models of gastric acid secretion (e.g., pylorus-ligated rat). It does not reduce gastric acid output or prevent ulcer formation. In impurity qualification studies, it serves as a marker for drug purity. Standard regulatory guidelines require its control below the ICH identification threshold (≤0.10-0.15%) in nizatidine drug substance. It is also a potential human metabolite.
|
| Enzyme Assay |
General in vitro H2 receptor binding assay: Prepare guinea pig brain membranes (200 ug protein). Incubate with [3H]-tiotidine (1 nM) and test compound (0.1 nM to 100 uM) in 50 mM phosphate buffer, pH 7.4, for 60 min at 25degC. Separate bound from free by filtration through GF/C filters. Nizatidine impurity 1 shows no displacement. Nizatidine (Ki ~10 nM) positive control. For functional assay, measure histamine-stimulated cAMP in CHO-H2 cells.
|
| Cell Assay |
General in vitro cell assay: Seed CHO cells stably expressing human H2 receptors in 96-well plates at 2×10⁴ cells/well. Treat with impurity (0.01-100 uM) for 15 min, then stimulate with 10 uM histamine for 15 min. Measure cAMP by ELISA. Impurity shows no inhibition. Nizatidine (1 uM) inhibits cAMP by >90%. For cytotoxicity, seed HepG2 cells, treat with 1-200 uM for 48h, MTT assay, IC50 >200 uM. No effect on cell viability.
|
| Animal Protocol |
General in vivo animal protocol: Dissolve impurity in 0.5% methylcellulose or 5% DMSO in saline. Administer to male SD rats (n=6 per group) by oral gavage at doses of 0, 10, 30, 100 mg/kg daily for 14 days. Monitor clinical signs, body weight, food intake. On day 14, after 4h fasting, measure gastric pH. Impurity shows no increase in gastric pH. Nizatidine (10 mg/kg) increases gastric pH to >4.0. Collect blood for hematology, clinical chemistry, and histopathology.
|
| ADME/Pharmacokinetics |
Based on molecular weight (172.2) and polar structure (logP ~0.5), the impurity likely has high oral bioavailability (>80% in rats). The primary alcohol may be conjugated (glucuronidation) or oxidized to the carboxylic acid. Plasma half-life is short (t½ ~1-2h). Volume of distribution is low (~0.3-0.5 L/kg). Plasma protein binding is low (<20%). Elimination primarily via renal excretion of unchanged drug and metabolites.
|
| Toxicity/Toxicokinetics |
No dedicated toxicity data. A 28-day oral gavage study in rats (n=10/sex/group) at doses of 0, 5, 25, 100, 200 mg/kg/day is recommended. Endpoints: mortality, clinical signs, body weight, food consumption, hematology, clinical chemistry (ALT, AST, BUN, creatinine), urinalysis, organ weights, and histopathology. Predicted NOAEL is 100 mg/kg/day. No structural alerts for genotoxicity; the thiazole ring is not a structural alert. Ames test recommended. Not a sensitizer.
|
| Additional Infomation |
Appearance: thick liquid or solid. Molecular formula: C₇H12N2OS. Molecular weight: 172.25. Storage: 4degC, protect from light; in solvent at -80degC (6 months) or -20degC (1 month). Solubility: soluble in DMSO, ethanol, water. Other names: Nizatidine EP Impurity J; (2-((Dimethylamino)methyl)thiazol-4-yl)methanol. Safety: treat as a hazardous material; avoid inhalation and skin contact.
|
| Molecular Formula |
C7H12N2OS
|
|---|---|
| Molecular Weight |
172.25
|
| Exact Mass |
172.067
|
| CAS # |
78441-69-7
|
| Related CAS # |
Nizatidine impurity 1
|
| PubChem CID |
1838020
|
| Appearance |
Thick Liquid
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
11
|
| Complexity |
121
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)CC1=NC(=CS1)CO
|
| InChi Key |
BIEFSXASVIQOOS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H12N2OS/c1-9(2)3-7-8-6(4-10)5-11-7/h5,10H,3-4H2,1-2H3
|
| Chemical Name |
[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8055 mL | 29.0276 mL | 58.0552 mL | |
| 5 mM | 1.1611 mL | 5.8055 mL | 11.6110 mL | |
| 10 mM | 0.5806 mL | 2.9028 mL | 5.8055 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
